No definition available.

Name:	ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix:	ions_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Cumulative amount of milestone payments, license fees and/or upfront fees received under the collaborative arrangement as of the end of the reporting period.

+ References

No definition available.

+ Details

Name:	ions_CumulativePaymentsAndOrFeesReceived
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the maximum amount of payments receivable per drug or program under the agreement.

+ References

No definition available.

+ Details

Name:	ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgram
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the next potential milestone payment to be earned.

+ References

No definition available.

+ Details

Name:	ions_NextPotentialMilestonePayment
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the number of drugs currently being advanced under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ions_NumberOfDrugsCurrentlyBeingAdvanced
Namespace Prefix:	ions_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Term of the collaboration agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	ions_TermOfCollaborationAgreement
Namespace Prefix:	ions_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=ions_BiogenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementSeptember2013Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=ions_StrategicNeurologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=ions_AntisenseMoleculeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ions_AchievementOfMilestoneAxis=ions_LicenseAndSubstantiveMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ions_AchievementOfMilestoneAxis=ions_ResearchAndDevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ions_AchievementOfMilestoneAxis=ions_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=ions_OtherModalitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ions_AchievementOfMilestoneAxis=ions_PreSpecifiedEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements and Licensing Agreements, Strategic Partnerships - Biogen (Strategic Neurology) (Details) $ in Thousands	1 Months Ended		3 Months Ended								12 Months Ended
	Dec. 31, 2015 USD ($)	Sep. 30, 2013 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2015 USD ($) Drug	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue earned			$ 51,571	$ 49,121	$ 120,428	$ 62,583	$ 84,861	$ 44,063	$ 57,076	$ 28,161	$ 283,703	$ 214,161	$ 147,285
Biogen [Member] \| Collaborations and Licensing Agreements [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue earned											106,200	123,200	$ 37,000
Deferred revenue	$ 91,600		91,600				$ 118,100				$ 91,600	$ 118,100
Biogen [Member] \| Collaborations and Licensing Agreements [Member] \| Revenue [Member] \| Strategic Partner [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Concentration percentage											37.00%	58.00%	25.00%
Biogen [Member] \| Agreement Entered into in September 2013 [Member] \| Strategic Neurology [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Number of drugs currently being advanced \| Drug											3
Upfront fee recorded as deferred revenue		$ 100,000
Term of collaboration agreement											6 years
Cumulative payments and/or fees received	135,000		135,000								$ 135,000
Milestone payment earned	5,000
Next potential milestone	10,000		10,000								10,000
Biogen [Member] \| Agreement Entered into in September 2013 [Member] \| Antisense Molecule [Member] \| License Fee and Substantive Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable per drug	260,000		260,000								260,000
Biogen [Member] \| Agreement Entered into in September 2013 [Member] \| Antisense Molecule [Member] \| Research and Development Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable per drug	60,000		60,000								60,000
Biogen [Member] \| Agreement Entered into in September 2013 [Member] \| Antisense Molecule [Member] \| Regulatory Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable per drug	130,000		130,000								130,000
Biogen [Member] \| Agreement Entered into in September 2013 [Member] \| Other Modalities [Member] \| Pre-Specified Events [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable per drug	90,000		90,000								90,000
Biogen [Member] \| Agreement Entered into in September 2013 [Member] \| Other Modalities [Member] \| Research and Development Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable per drug	35,000		35,000								35,000
Biogen [Member] \| Agreement Entered into in September 2013 [Member] \| Other Modalities [Member] \| Regulatory Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable per drug	$ 55,000		$ 55,000								$ 55,000